Cargando…
Modeling and control of epidemics through testing policies()
Testing is a crucial control mechanism in the beginning phase of an epidemic when the vaccines are not yet available. It enables the public health authority to detect and isolate the infected cases from the population, thereby limiting the disease transmission to susceptible people. However, despite...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Ltd.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8514419/ https://www.ncbi.nlm.nih.gov/pubmed/34664008 http://dx.doi.org/10.1016/j.arcontrol.2021.09.004 |
_version_ | 1784583379466846208 |
---|---|
author | Niazi, Muhammad Umar B. Kibangou, Alain Canudas-de-Wit, Carlos Nikitin, Denis Tumash, Liudmila Bliman, Pierre-Alexandre |
author_facet | Niazi, Muhammad Umar B. Kibangou, Alain Canudas-de-Wit, Carlos Nikitin, Denis Tumash, Liudmila Bliman, Pierre-Alexandre |
author_sort | Niazi, Muhammad Umar B. |
collection | PubMed |
description | Testing is a crucial control mechanism in the beginning phase of an epidemic when the vaccines are not yet available. It enables the public health authority to detect and isolate the infected cases from the population, thereby limiting the disease transmission to susceptible people. However, despite the significance of testing in epidemic control, the recent literature on the subject lacks a control-theoretic perspective. In this paper, an epidemic model is proposed that incorporates the testing rate as a control input and differentiates the undetected infected from the detected infected cases, who are assumed to be removed from the disease spreading process in the population. After estimating the model on the data corresponding to the beginning phase of COVID-19 in France, two testing policies are proposed: the so-called best-effort strategy for testing (BEST) and constant optimal strategy for testing (COST). The BEST policy is a suppression strategy that provides a minimum testing rate that stops the growth of the epidemic when implemented. The COST policy, on the other hand, is a mitigation strategy that provides an optimal value of testing rate minimizing the peak value of the infected population when the total stockpile of tests is limited. Both testing policies are evaluated by their impact on the number of active intensive care unit (ICU) cases and the cumulative number of deaths for the COVID-19 case of France. |
format | Online Article Text |
id | pubmed-8514419 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Elsevier Ltd. |
record_format | MEDLINE/PubMed |
spelling | pubmed-85144192021-10-14 Modeling and control of epidemics through testing policies() Niazi, Muhammad Umar B. Kibangou, Alain Canudas-de-Wit, Carlos Nikitin, Denis Tumash, Liudmila Bliman, Pierre-Alexandre Annu Rev Control Full Length Article Testing is a crucial control mechanism in the beginning phase of an epidemic when the vaccines are not yet available. It enables the public health authority to detect and isolate the infected cases from the population, thereby limiting the disease transmission to susceptible people. However, despite the significance of testing in epidemic control, the recent literature on the subject lacks a control-theoretic perspective. In this paper, an epidemic model is proposed that incorporates the testing rate as a control input and differentiates the undetected infected from the detected infected cases, who are assumed to be removed from the disease spreading process in the population. After estimating the model on the data corresponding to the beginning phase of COVID-19 in France, two testing policies are proposed: the so-called best-effort strategy for testing (BEST) and constant optimal strategy for testing (COST). The BEST policy is a suppression strategy that provides a minimum testing rate that stops the growth of the epidemic when implemented. The COST policy, on the other hand, is a mitigation strategy that provides an optimal value of testing rate minimizing the peak value of the infected population when the total stockpile of tests is limited. Both testing policies are evaluated by their impact on the number of active intensive care unit (ICU) cases and the cumulative number of deaths for the COVID-19 case of France. Elsevier Ltd. 2021 2021-10-14 /pmc/articles/PMC8514419/ /pubmed/34664008 http://dx.doi.org/10.1016/j.arcontrol.2021.09.004 Text en © 2021 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Full Length Article Niazi, Muhammad Umar B. Kibangou, Alain Canudas-de-Wit, Carlos Nikitin, Denis Tumash, Liudmila Bliman, Pierre-Alexandre Modeling and control of epidemics through testing policies() |
title | Modeling and control of epidemics through testing policies() |
title_full | Modeling and control of epidemics through testing policies() |
title_fullStr | Modeling and control of epidemics through testing policies() |
title_full_unstemmed | Modeling and control of epidemics through testing policies() |
title_short | Modeling and control of epidemics through testing policies() |
title_sort | modeling and control of epidemics through testing policies() |
topic | Full Length Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8514419/ https://www.ncbi.nlm.nih.gov/pubmed/34664008 http://dx.doi.org/10.1016/j.arcontrol.2021.09.004 |
work_keys_str_mv | AT niazimuhammadumarb modelingandcontrolofepidemicsthroughtestingpolicies AT kibangoualain modelingandcontrolofepidemicsthroughtestingpolicies AT canudasdewitcarlos modelingandcontrolofepidemicsthroughtestingpolicies AT nikitindenis modelingandcontrolofepidemicsthroughtestingpolicies AT tumashliudmila modelingandcontrolofepidemicsthroughtestingpolicies AT blimanpierrealexandre modelingandcontrolofepidemicsthroughtestingpolicies |